Clinical effect of driver mutations of JAK2, CALR, or MPLin primary myelofibrosis

We studied the impact of driver mutations of JAK2, CALR, (calreticulin gene) or MPLon clinical course, leukemic transformation, and survival of patients with primary myelofibrosis (PMF). Of the 617 subjects studied, 399 (64.7%) carried JAK2(V617F), 140 (22.7%) had a CALRexon 9 indel, 25 (4.0%) carried an MPL(W515) mutation, and 53 (8.6%) had nonmutated JAK2, CALR, and MPL(so-called triple-negative PMF). Patients with CALRmutation had a lower risk of developing anemia, thrombocytopenia, and marked leukocytosis compared with other subtypes. They also had a lower risk of thrombosis compared with patients carrying JAK2(V617F). At the opposite, triple-negative patients had higher incidence of leukemic transformation compared with either CALR-mutant or JAK2-mutant patients. Median overall survival was 17.7 years in CALR-mutant, 9.2 years in JAK2-mutant, 9.1 years in MPL-mutant, and 3.2 years in triple-negative patients. In multivariate analysis corrected for age, CALR-mutant patients had better overall survival than either JAK2-mutant or triple-negative patients. The impact of genetic lesions on survival was independent of current prognostic scoring systems. These observations indicate that driver mutations define distinct disease entities within PMF. Accounting for them is not only relevant to clinical decision-making, but should also be considered in designing clinical trials.